Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream
Additional submissions slated for France, Germany, Greece, .
Research Article
Effectiveness of a primary care-based integrated mobile health intervention for stroke management in rural China (SINEMA): A cluster-randomized controlled trial
Lijing L. Yan , Contributed equally to this work with: Lijing L. Yan, Enying Gong Roles Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Writing – original draft, Writing – review & editing
Affiliations Global Health Research Center, Duke Kunshan University, Jiangsu, China, Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America, The George Institute for Global Health, Beijing, China, School of Health Sciences, Wuhan University, Wuhan, Hubei, China, Peking University School of Global Health and Development, Beijing, China
Published: Apr 26, 2021
Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced the U.S. Food and Drug Administration (FDA) has removed its clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01, a gene therapy candidate for the treatment of Huntington’s disease (HD), and confirmed that the company may proceed with its planned Phase 1/2 clinical trial. The decision was made following a comprehensive review of the Chemistry, Manufacturing and Controls information previously submitted to the FDA. Voyager plans to initiate VYTAL, a Phase 1/2 clinical trial of VY-HTT01, this year.
Contract Research Organization Market Revenue to Cross USD 74 2 Bn by 2027: Global Market Insights Inc prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
UConn study needs older people, but too many are vaccinated
FacebookTwitterEmail
Lucy Gagliano, 75, is vaccinated, Wednesday, Feb. 10, 2021, at Central High School in Bridgeport, Conn. The mass vaccination clinic is one of several ways Bridgeport officials are trying to fight the low vaccination rates many cities across the country are seeing compared with wealthier suburbs. (AP Photo/Mark Lennihan)Mark Lennihan / Associated Press
For a few researchers in Connecticut, the state may have done too good of a job vaccinating older people.
George Kuchel and his team at UConn’s Center on Aging have been trying to study, in great detail, why vaccines and the virus itself impact older people so much more.